Man Group’s Capricor Therapeutics CAPR Stock Holding History

Man Group’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-84,654	Closed	-$404K	–	1989
2024 Q2	$404K	Buy	84,654 +11,757	+16%	+$65.6K	﹤0.01%	1732
2024 Q1	$495K	Buy	+72,897	New	+$352K	﹤0.01%	1784

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Man Group's CAPR Position: Q3 2024 in Review

Man Group sold out of Capricor Therapeutics (CAPR) in Q3 2024, closing a stake of 84,654 shares — an estimated $404K sold.

Man Group first reported a position in CAPR in Q1 2024 and held it in 2 quarters. The position peaked at $495K in Q1 2024. 75 funds tracked by Wall St. Rank hold CAPR as of Q3 2024.

Man Group reported no remaining Capricor Therapeutics position as of Q3 2024 after selling out during the quarter.
Man Group sold 84,654 Capricor Therapeutics shares in Q3 2024, an estimated $404K.
Man Group first reported a position in Capricor Therapeutics in Q1 2024 and held it in 2 quarters.
Man Group's Capricor Therapeutics position peaked at $495K in Q1 2024.
75 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.